Key facts
- This page summarizes Ansbert Gadicke's Form 4 filing for Harpoon Therapeutics, Inc..
- 5 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 02 Jun 2021, 18:09.
Ansbert Gadicke - 28 May 2021 Form 4 Insider Report for Harpoon Therapeutics, Inc.
- Reporting relationship
- 10%+ Owner
- Issuer ticker
- N/A
- Reported as of
- 28 May 2021
- Net transaction value
- -$1,186,190
- SEC form
- 4
- Accepted by SEC
- 02 Jun 2021, 18:09:39 UTC
- Prior SEC filing
- 27 May 2021
- Next SEC filing
- 07 Jun 2021
- Source filing
- View source filing
- Reporting owner signature
- /s/ Ansbert Gadicke
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Ansbert Gadicke filed Form 4 for Harpoon Therapeutics, Inc. on 02 Jun 2021.
Change
- Previous filing in this sequence was filed on 27 May 2021.
- Current net transaction value: -$1,186,190.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
HARP
transaction
Common Stock
Sale
- Transaction value
- $223,103
- Shares
- -10,685
- Change %
- -0.17%
- Price
- $20.88*
- Shares after
- 6,374,904
- Date
- 28 May 2021
- Ownership
- See Footnote
- Footnotes
- F1, F2, F3, F4
HARP
transaction
Common Stock
Sale
- Transaction value
- $67,952
- Shares
- -3,100
- Change %
- -0.05%
- Price
- $21.92*
- Shares after
- 6,371,804
- Date
- 28 May 2021
- Ownership
- See Footnote
- Footnotes
- F1, F5, F6, F7
HARP
transaction
Common Stock
Sale
- Transaction value
- $2,260
- Shares
- -100
- Change %
- -0%
- Price
- $22.60*
- Shares after
- 6,371,704
- Date
- 28 May 2021
- Ownership
- See Footnote
- Footnotes
- F1, F8, F9
HARP
transaction
Common Stock
Sale
- Transaction value
- $377,956
- Shares
- -18,491
- Change %
- -0.29%
- Price
- $20.44*
- Shares after
- 6,353,213
- Date
- 01 Jun 2021
- Ownership
- See Footnote
- Footnotes
- F1, F10, F11, F12
HARP
transaction
Common Stock
Sale
- Transaction value
- $514,919
- Shares
- -25,118
- Change %
- -0.4%
- Price
- $20.50*
- Shares after
- 6,328,095
- Date
- 02 Jun 2021
- Ownership
- See Footnote
- Footnotes
- F1, F13, F14, F15
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 15 footnotes
Footnote F1
Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/16/2021.
Footnote F2
The shares were sold as follows: 9,392 by UBS Oncology Impact Fund, L.P. ("UBS Oncology") and 1,293 by MPM Asset Management LLC ("AM LLC").
Footnote F3
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.52 to $21.50 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Footnote F4
The shares are held as follows: 2,657,097 by MPM BioVentures 2014, L.P. ("BV 2014"), 152,470 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 96,376 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 231,110 by AM LLC and 3,237,851 by UBS Oncology. MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). MPM Oncology Impact Management GP LLC ("Oncology GP LLC") is the General Partner of MPM Oncology Impact Management LP, the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. BV LLC is the manager of AM BV2014. Messrs. Evnin, Gadicke and Foley are the members of BV LLC and Messrs. Evnin and Gadicke are the members of AM LLC. Mr. Gadicke is the Managing Member of Oncology GP LLC. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein.
Footnote F5
The shares were sold as follows: 2,725 by UBS Oncology and 375 by AM LLC.
Footnote F6
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.58 to $22.50 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Footnote F7
The shares are held as follows: 2,657,097 by BV 2014, 152,470 by BV 2014(B), 96,376 by AM BV2014, 230,735 by AM LLC and 3,235,126 by UBS Oncology. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein.
Footnote F8
The shares were sold as follows: 88 by UBS Oncology and 12 by AM LLC.
Footnote F9
The shares are held as follows: 2,657,097 by BV 2014, 152,470 by BV 2014(B), 96,376 by AM BV2014, 230,723 by AM LLC and 3,235,038 by UBS Oncology. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein.
Footnote F10
The shares were sold as follows: 16,253 by UBS Oncology and 2,238 by AM LLC.
Footnote F11
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.74 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Footnote F12
The shares are held as follows: 2,657,097 by BV 2014, 152,470 by BV 2014(B), 96,376 by AM BV2014, 228,485 by AM LLC and 3,218,785 by UBS Oncology. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein.
Footnote F13
The shares were sold as follows: 22,078 by UBS Oncology and 3,040 by AM LLC.
Footnote F14
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.24 to $20.76 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Footnote F15
The shares are held as follows: 2,657,097 by BV 2014, 152,470 by BV 2014(B), 96,376 by AM BV2014, 225,445 by AM LLC and 3,196,707 by UBS Oncology. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein.